A
Anne Boerekamps
Researcher at Erasmus University Rotterdam
Publications - 13
Citations - 328
Anne Boerekamps is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Men who have sex with men & Hepatitis C. The author has an hindex of 6, co-authored 10 publications receiving 253 citations.
Papers
More filters
Journal ArticleDOI
Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy
Anne Boerekamps,Guido E.L. van den Berk,F. N. Lauw,Eliane M. S. Leyten,Marjo E. E. van Kasteren,Arne van Eeden,Dirk Posthouwer,Mark A. A. Claassen,Anton S M Dofferhoff,D. W. M. Verhagen,Wouter F W Bierman,Kamilla D. Lettinga,Frank P. Kroon,Corine E Delsing,Paul H. P. Groeneveld,Robert Soetekouw,Edgar J G Peters,Sebastiaan J. Hullegie,Stephanie Popping,David A. M. C. van de Vijver,Charles A. Boucher,Joop E. Arends,Bart J. A. Rijnders +22 more
TL;DR: Unrestricted DAA availability in the Netherlands was followed by a 51% decrease in acute HCV infections among HIV-positive MSM, which contradicts a decrease in risk behavior as an alternative explanation.
Journal ArticleDOI
High treatment uptake in human immunodeficiency virus/ hepatitis C virus-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands
Anne Boerekamps,Astrid M. Newsum,Colette Smit,Joop E. Arends,Clemens Richter,Peter Reiss,Bart J. A. Rijnders,Kees Brinkman,Marc van der Valk +8 more
TL;DR: Fifteen months after unrestricted DAA availability the majority of HIV/HCV-coinfected patients in the Netherlands have their HCV infection cured or are awaiting DAA treatment results, which may contribute to future HCV elimination among these patients.
Journal ArticleDOI
Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it
TL;DR: The modelling evidence and cost data surrounding feasibility of HCV elimination among people living with HIV (PLWH) are reviewed, and likely components for elimination are identified.
Journal ArticleDOI
Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men.
Stephanie Popping,Sebastiaan J. Hullegie,Anne Boerekamps,Bart J. A. Rijnders,Robert J. de Knegt,Jürgen K. Rockstroh,Annelies Verbon,Charles A. Boucher,Brooke E Nichols,Brooke E Nichols,David A. M. C. van de Vijver +10 more
TL;DR: Early DAA treatment for HIV-infected MSM is an excellent and sustainable tool to meet the WHO goal of eliminating HCV in 2030.
Journal ArticleDOI
Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial
Anne Boerekamps,Anja De Weggheleire,Guido E.L. van den Berk,F. N. Lauw,Mark A. A. Claassen,Dirk Posthouwer,Wouter F W Bierman,Sebastiaan J. Hullegie,Stephanie Popping,David A C M van de Vijver,Anthonius S. M. Dofferhoff,Gert Jan Kootstra,Eliane M. S. Leyten,Jan G den Hollander,Marjo E. E. van Kasteren,Robert Soetekouw,Heidi S. M. Ammerlaan,Janke Schinkel,Eric Florence,Joop E. Arends,Bart J. A. Rijnders +20 more
TL;DR: 8 weeks of grazoprevir plus elbasvir was highly effective for the treatment of acute HCV genotype 1 or 4 infection and whether treatment can be shortened during the acute phase of HCV infection is investigated.